Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Fish oil + soybean oil + olive oil + medium-chain triglycerides** is a four-oil intravenous lipid injectable emulsion marketed as **SMOFlipid** by Fresenius Kabi. It supplies calories and essential fatty acids as part of parenteral nutrition for adult and pediatric patients, including term and preterm neonates, when oral or enteral nutrition is not possible, insufficient, or contraindicated. The emulsion contains soybean oil, medium-chain triglycerides, olive oil, and fish oil, providing omega-6 and omega-3 fatty acids alongside medium-chain and monounsaturated triglycerides. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/207648s013lbl.pdf))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fish oil + soybean oil + olive oil + medium-chain triglycerides.